Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HA1 | P13674 | 3/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886683 | 0.80 | ALDH1A1 (0.58) | P4HA1P4HTMALDH1A1HSD17B10KDM4E | |
| SCHEMBL23193160 | 0.77 | NNMT (0.50) | P4HA1P4HTMHSD17B10KDM4ECYP2C19 | |
| SCHEMBL185448 | 0.76 | ALDH1A1 (0.54) | P4HA1P4HTMALDH1A1HSD17B10KDM4E | |
| SCHEMBL3705899 | 0.76 | ALDH1A1 (0.54) | P4HA1P4HTMALDH1A1HSD17B10KDM4E | |
| SCHEMBL11457022 | 0.75 | ALDH1A1 (0.58) | ALDH1A1ALOX15LDHAMAPT | |
| SCHEMBL63857 | 0.74 | NAPRT (0.58) | P4HA1P4HTMALDH1A1HSD17B10KDM4E | |
| SCHEMBL16749632 | 0.74 | ALDH1A1 (0.52) | P4HA1P4HTMALDH1A1HSD17B10KDM4E | |
| SCHEMBL186175 | 0.74 | GABRP (0.58) | P4HA1P4HTMALDH1A1HSD17B10KDM4E | |
| SCHEMBL4600260 | 0.74 | ALDH1A1 (0.52) | P4HA1P4HTMALDH1A1HSD17B10KDM4E | |
| SCHEMBL29345465 | 0.74 | ALDH1A1 (0.52) | P4HA1P4HTMALDH1A1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105683202-B | Boric acid compound | SYNTRIX生物系统公司 | 2019-05-10 | — | — | CN | claimed |
| CN-105683202-A | 2- [5- [ N- (4-fluorophenyl) carbamoyl ] pyrimidin-2-ylmethylsulfanylmethyl ] -4- (trifluoromethoxy) phenyl ] boronic acid | SYNTRIX生物系统公司 | 2016-06-15 | — | — | CN | claimed |
| EP-3027627-A1 | 2- [5- [N- (4 -FLUOROPHENYL) CARBAMOYL]PYRIMIDIN- 2 - YLSULFANYLMETHYL]-4- (TRIFLUOROMET HOXY) PHENYL]BORONIC ACID | Syntrix Biosystems, Inc. (US) | 2016-06-08 | — | — | EP | claimed |
| US-8969365-B2 | Thiopyrimidinecarboxamides as CXCR1/2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-03 | — | — | US | claimed |
| WO-2015016938-A1 | 2- [5- [N- (4 -FLUOROPHENYL) CARBAMOYL] PYRIMIDIN- 2 - YLSULFANYLMETHYL] -4- (TRIFLUOROMET HOXY) PHENYL] BORONIC ACID | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-02-05 | — | — | WO | claimed |
| US-20150038461-A1 | THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-02-05 | — | — | US | claimed |
| US-11022880-B2 | Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-10561676-B2 | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 | SYNTRIX BIOSYSTEMS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| CN-110200979-A | A kind of boronic acid compounds | SYNTRIX生物系统公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-107312012-B | Pyrimido phenodiazine * analog derivative and its medical usage | 北京师范大学 | 2019-07-12 | — | — | CN | disclosed |
| CN-105683202-B | Boric acid compound | SYNTRIX生物系统公司 | 2019-05-10 | — | — | CN | disclosed |
| US-10130645-B2 | Use of thiopyrimidinecarboxamide for treating cancer | SYNTRIX BIOSYSTEMS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180296580-A1 | METHOD FOR TREATING CANCER USING DUAL ANTAGONISTS OF CXCR1 AND CXCR2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-18 | — | — | US | disclosed |
| EP-1119528-B1 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LTD (GB) | 2002-08-28 | — | — | EP | disclosed |
| EP-1218319-A1 | CHEMICAL CONSTRUCTS | GLAXO GROUP LIMITED (GB) | 2002-07-03 | — | — | EP | disclosed |
| EP-1119528-A2 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2001-08-01 | — | — | EP | disclosed |
| EP-1119529-A2 | CHEMICAL CONSTRUCTS | GLAXO GROUP LIMITED (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2001025171-A1 | CHEMICAL CONSTRUCTS | GLAXO GROUP LIMITED (GB) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000020357-A2 | CHEMICAL CONSTRUCTS | GLAXO GROUP LIMITED (GB) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020112-A2 | CHEMICAL CONSTRUCTS AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038461-A1 | THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS | CXCR1, CXCR5, CXCR2 | P4HA1 1645/4885P4HTM 1846/4885ALDH1A1 1648/4885 |
| US-11022880-B2 | Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound | CUTA, POLR1C, ASIC1 | P4HA1 1935/4885P4HTM 1981/4885ALDH1A1 639/4885 |
| US-10561676-B2 | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 | CXCR2, CXCR1, CXCR5 | P4HA1 964/4885P4HTM 1786/4885ALDH1A1 2100/4885 |
| US-20180296580-A1 | METHOD FOR TREATING CANCER USING DUAL ANTAGONISTS OF CXCR1 AND CXCR2 | CXCR2, CXCR1, CXCR5 | P4HA1 964/4885P4HTM 1786/4885ALDH1A1 2100/4885 |
| US-10130645-B2 | Use of thiopyrimidinecarboxamide for treating cancer | TYMP, FLT4, VEGFA | P4HA1 1596/4885P4HTM 1856/4885ALDH1A1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.